Recent studies have demonstrated that protein C deficiency is associated with recurrent familial thrombosis. In plasma, activated protein C functions as an anticoagulant. This anticoagulant response requires a vitamin K-dependent plasma protein cofactor, referred to as protein S. Since the anticoagulant activity of activated protein C is dependent on protein S, we hypothesized that patients lacking functional protein S might have associated thrombotic disease. Two related individuals with otherwise normal coagulation tests are described whose plasma is not effectively anticoagulated with activated protein C. Addition of purified human protein S to their plasma restores a normal anticoagulant response to activated protein C. We have developed a rapid one-stage clotting assay for protein S to quantitate the level of protein S in their plasma. Plasma is depleted of protein S by immunoadsorption with immobilized antiprotein S antibodies. The resultant plasma responds poorly to activated protein C, but is effectively anticoagulated in a dose-dependent fashion upon addition of purified protein S or small quantities of plasma. The affected individuals possess less than 5% protein S activity. Using Laurell rockets, protein S antigen was detected in the plasma but was at reduced levels of 13 and 18% in the two individuals. When the barium eluate of the patient plasma was chromatographed on quaternary aminoethyl Sephadex, a single peak of protein S antigen devoid […] peak of protein S antigen devoid of protein S anticoagulant cofactor activity was detected early in the chromatogram. In contrast, the barium eluate from normal donors separated into two peaks, one emerging early and also devoid of anticoagulant cofactor, and the second peak with anticoagulant activity emerging later. The first peak of protein S antigen, from both the normal donor and the patient, chromatographed in the region of the complement component C4-binding protein-protein S complex. These studies suggest that protein S deficiency may result in recurrent thrombotic disease.
Abstract. Recent 
Introduction
Protein S is a vitamin K-dependent plasma protein that was discovered in 1977 (1) . At that time, no function was ascribed to protein S. Recently, a role for protein S in the expression of activated protein C anticoagulant activity has been proposed (2) . Activated protein C inhibits the blood clotting cascade at the levels of Factor V and Factor VIII. In normal plasma, as little as 0.1 tg/ml activated protein C results in significant prolongation of the plasma clotting time. In 1980, Walker observed that protein S-deficient plasma was no longer effectively anticoagulated by activated protein C (2) . Subsequent studies revealed that protein S serves as a cofactor for activated protein C (3, 4) . Protein S forms a 1:1 complex with activated protein C on the surface of membranes (3) . This 7.5 . All of these steps were at 220C. The eluate containing the vitamin K-dependent factors was pooled and diluted 1:2.7 in 0.01 M Na oxalate, 5 mM benzamidine HCO, 0.02 M Tris HC1, pH 7.5. The eluate was adsorbed onto 500 g of BaSO4 by gentle mixing for 1 h, and the BaSO4 was harvested by centrifugation at 2,500 g for 5 min at 4°C. The pellet was resuspended in 2 liters of 0.078 M NaCO, 1 mM Na citrate, 10 mM Tris HCO, 1 mM benzamidine HCO, pH 7.5. The BaSO4 was harvested by centrifugation as described above. The vitamin K-dependent factors were eluted from the BaSO4 by suspension in 2 liters of 0.1 M Na citrate, pH 5.8. The BaSO4 was harvested by centrifugation as described above, and eluted a second time with 2 liters of the citrate buffer. The two eluates were pooled.
The pooled eluates were diluted 1:3.3 into 0.02 M Tris HCO, 5 mM benzamidine HCO, pH 7.5, and the vitamin K-dependent factors were adsorbed onto QAE Sephadex Q50 (150 ml settled volume), and equilibrated in 0.18 M NaCO, 5 mM 24N-morpholino)ethanesulfonic acid (MES)', 5 mM benzamidine HCO, pH 6.0, for 1 h at 22°C. The QAE Sephadex was allowed to settle for 30 min, the supernatant was removed by siphoning, and the QAE Sephadex was collected in a Buchner funnel overlayed with nylon cloth, and washed with 200 ml of 0.18 M NaCO, 5 mM MES, 5 mM benzamidine HCI, pH 6.0. A thick slurry of this QAE Sephadex was then packed on top of a prepacked 2.5 X 90 cm column of QAE Sephadex Q50 equilibrated in this same buffer to give a total column height of 120 cm. From melting the plasma to this step requires 10 h. The column was developed at 4°C with a linear gradient (1 liter/reservoir) from 0.18 to 0.5 M NaCO in 5 mM MES, 5 mM benzamidine HCO, pH 6.0. The column requires '30 h to develop. Protein C and protein S emerged in front of the prothrombin peak, and were almost completely resolved from prothrombin. The protein S emerged slightly ahead of the protein C, and the two proteins were only partially resolved.
Protein S was further purified by a modification of the method of Dahlback and Stenflo (8) . Routinely, the protein S peak was identified by the functional protein S assay described below. Protein C was removed from the protein S by adsorption on a murine monoclonal IgG antibody to human protein C coupled to Affigel 10 (Bio-Rad Laboratories, Richmond, CA). The protein S peak was partially purified by (NH4.SO4 fractionation. Solid (NH4)2SO4 was added at 4VC to bring the sample to 25% saturation, and stirred for 30 min. The precipitate was removed by centrifigation at 15,000 g for 30 min at 4VC. The supernatant containing the protein S was brought to 70% saturation by adding (NH4.SO4, and stirred for 30 min. The pellet was collected by centrifugation as described above. The pellet was resuspended in 5-10 ml of 50 mM Tris HCI, pH 7.5, and 2 mM diisopropyl fluorophosphate. The precipitate (10 ml, 5 mg/ml) was dialyzed against 0.05 M NaCl, 1 mM EDTA, 1 mM benzamidine HCO, 0.02% Na azide, 50 mM Tris HCO, pH 7.5, and chromatographed on a blue Sepharose column (1.5 X 52 cm) at 220C. The column was developed with a linear gradient from 0.05 M NaCI to 0.2 M NaCl (150 ml/reservoir) in 1 mM EDTA, 1 mM benzamidine, 50 mM Tris HCO, pH 7.5. Protein S activity was detected in the first protein peak to emerge from the column. Most of the trace contaminants were separated from the protein S by chromatography at 22°C on a column (0.6 X 25 cm) of heparin-agarose. The heparin was linked to Biogel A 15 M (20040 mesh; Bio-Rad Laboratories) as described previously (9) for linkage to Bio-Gel A 5 M. The protein S peak from the blue Sepharose was dialyzed into 0.05 M imidazole HCO, 1 mM benzamidine HCI, 1 mM CaCl2, pH 6.0 before application to the heparin-agarose column previously equilibrated in the above buffer. The column was developed with a linear gradient (30 ml/reservoir) containing the equilibration buffer in the lead reservoir, and 0.05 M imidazole HCO, I mM EDTA, 1 mM benzamidine HC1, pH 6.0, in the trailing buffer. Protein S activity was associated with the last protein peak to emerge from the column. This peak constituted >80% of the applied protein.
The protein S prepared in this manner is shown in Fig. 1 .
Treatment of the purified protein S with thrombin destroyed the ability to serve as a cofactor for activated protein C as previously reported by others (4) (Fig. 2) . The loss of the activated protein C cofactor activity correlated with the disappearance of the protein S as monitored on polyacrylamide gels (Fig. 3) .
Protein C and activated protein C were prepared either by conventional chromatographic methods (7) or by chromatography on a murine IgG monoclonal antihuman protein C antibody. Briefly, this antibody is conformationally specific and requires Ca2+ for interaction with protein C. Removal of Ca2' results in elution of human protein C (unpublished data). Protein C and activated protein C prepared by either method functioned identically in the protein S functional assay.
Laurell rocket electrophoresis of protein S. Protein S in human plasma circulates both as a free protein and as a complex with complement component C4-binding protein (C4bp) (10). The complex does not dissociate during conventional agarose gel electrophoresis (1 1). To estimate immunologic levels of protein S, conventional Laurell rocket electrophoresis was employed with 7 mM EDTA, and with 2% polyethylene glycol 6,000 in the agar plates. Agarose used in the plates (1% Seakem ME agarose, FMC Corp., Marine Colloids Div., Rockland, ME) was made up with Paragon B-2 buffer (Beckman Instruments Inc., Fullerton, CA). The same buffer with 7 mM EDTA added was employed for electrophoresis. Goat IgG directed against human proteins S and C was produced as previously described (7 At times indicated, aliquots were removed and denatured by addition of sodium dodecyl sulfate and beta-mercaptoethanol, and immediate immersion of the tubes containing the samples in a boiling waterbath. Samples were electrophoresed on 10% polyacrylamide gels. Gel 1, unreduced starting protein S; gel 2, reduced starting protein S; gels 3, 4, 5, and 6, reduced samples at 15 s, 2 min, 5 min, and 30 min. The band with relative mobility of 58% is thrombin. Protein S incubated without thrombin showed no degradation.
the antibody against 0.1 M 3-(N-morpholino)propanesulfonic acid, pH 7.5. The antibody was bound at -10 mg/ml gel. A 1.5 X 10 cm goatantihuman protein S column was prepared and washed extensively in 20 mM Tris buffer, pH 7.4, containing 0.1 M NaCl. Over this column 35 ml citrated normal human plasma was passed at 7 ml/h. Fractions containing the plasma were then pooled. No protein S could be detected in the pooled deficient plasma by rocket immunoelectrophoresis or by the functional assay. The protein S-deficient plasma contained normal levels of Factors X and V, assayed as previously described (12, 13) , and normal levels of protein C, measured functionally and immunologically (7). The activated partial thromboplastin and prothrombin times were unchanged after immunoadsorption. Functional protein S assay. The assay is based on the ability of protein S to serve as a cofactor of the anticoagulant effects of activated protein C. Plasmas from patients on warfarin therapy or from patients with liver failure have increased sensitivity to the anticoagulant effects of activated protein C. The standard dilutional curves generated using these plasmas are not parallel to that made by mixing normal plasma with protein S-deficient plasma. This assay is, therefore, not appropriate for these patients.
Barium adsorption precipitation, elution, and chromatography of patient plasma. 8 ml of 1 M barium chloride was slowly added with constant stirring to 100 ml of citrated patient plasma containing 1 mM benzamidine at 4VC. The barium citrate precipitate was collected by centrifugation at 2,000 rpm at 4VC for 10 min. No protein S could be detected immunologically in the supernatant. The surface of the precipitate was washed with 5 ml of cold 20 mM Tris buffer, pH 7.4, containing 0.1 M NaCl, and the precipitate was resuspended in 10 ml 0.2 M Tris buffer, pH 7.4, containing 0.2 M EDTA and 1 mM benzamidine. When the precipitate had dissolved with gentle stirring, the barium eluate was desalted on a G-75 Sephadex column (2.5 X 50 cm), equilibrated, and developed with 5 mM MES buffer, pH 6.0, containing 0.2 M NaCl. Fractions containing eluted proteins from this column were loaded on a 0.6 X 40 cm QAE-Sephadex column equilibrated with 5 mM MES buffer, pH 6.0, containing 0.2 M NaCl. The Normal plasma samples for determining normal ranges and for making a normal pool were obtained from 20 healthy individuals, not on anticoagulant therapy, and with no personal or family history of thrombosis, ranging from 21 to 62 yr of age.
Results
Normal plasma is anticoagulated by activated protein C. The addition of activated protein C to the plasma of two brothers with severe recurrent venous thrombosis did not anticoagulate their plasma, as evidenced by no significant change in the clotting time after additional activated protein C (Table I) . Plasma was supplemented with activated protein C (0.56 sg/ml concentration in plasma) immediately before determination of the clotting time, as was protein S (final concentration, 20 sg/ml in plasma). Three determinations were made on each sample. Addition of protein S alone did not significantly change the clotting times determined for the plasma samples without added activated protein C.
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When the plasma of these two individuals was supplemented with purified protein S, the addition of activated protein C resulted in anticoagulation. The addition of protein S alone did not affect the clotting time.
To quantitate the functional protein S activity present in the patients' plasma, we developed the functional protein S assay described in Methods. Using this assay, we determined that normal individuals have protein S activity between 160 and 68% with a mean of 100%. We also determined that the brothers with recurrent thrombosis had no detectable protein S activity (Fig. 5) , whereas two other siblings and one grandparent had normal levels of protein S. The mother and father had reduced levels of 30 and 15%, respectively. Neither parent has had any thrombotic disease.
To determine if any immunologically functional levels of detectable protein S were present in the plasma of the deficient brothers, Laurell rocket electrophoresis was carried out. Analysis of the plasma of the brothers with thrombosis (Fig. 6 ) revealed levels of 18 and 13% for W.G. and E.G., respectively. Certain other family members had less immunoprecipitable protein S than normal plasma. These included the mother with 49%, the father with 71%, and an unaffected younger brother with 50%. Protein S is known to exist in plasma both free and complexed to complement component C4bp (8) . Note that the immunoelectrophotic technique employed does not permit quantitation of the relative amount of free protein S versus the amount of protein S in the protein S-C4bp complex.
We wished to determine if any free, but functionally inactive, protein S could be identified in the plasma of the functionally deficient individuals. To determine this, plasma from the brother with 18% immunologically detectable protein S was subjected to barium citrate adsorption and elution to concentrate the vitamin K-dependent plasma proteins. The barium eluate was then subjected to ion exchange chromatography (Fig. 7) . As has been seen by others (10), the barium eluate from normal plasma contained two distinct peaks of immunologically detectable protein S: the first peak in the region of the protein S-C4bp complex, and the second peak in the region where free protein S is eluted. Functional protein S activity is associated with the second (free) protein S peak. The barium eluate from the patient plasma contained only a single protein S peak, eluting from the column in the region of the protein S-C4bp complex. No protein S activity was present. The Laurell rockets of these two columns are shown 12 3 4 5 6 7 8 9 10 Figure 6 . Laurell rocket electrophoretic analysis of a protein S. deficient family. Wells 1-3, 100, 50, and 25% pooled normal plasma; well 4, grandmother (104%); well 5, father (71%); well 6, mother (49%); well 7, proband (13%); well 8, protein S-deficient brother (19%); wells 9 and 10, unaffected brother and sister. Ag/ml, and 10 Ag/ml purified protein S. Evennumbered column fractions were analysed as inIn dicated across column eluates.
in Fig. 8 . The rockets from the protein S-C4bp peak have immunoprecipitated material inside them, suggesting continuous separation of the C4bp complex during electrophoresis. The rockets in the region of the free protein S give a sharp outline closely resembling that seen with purified protein S. The previous demonstration that both brothers responded to addition of purified protein S suggested that their deficiency was not due to the presence of an inhibitor. To exclude the possible presence of a slow-acting inhibitor, normal plasma was combined in equal parts with plasma from each of the two brothers. The plasma mixtures were incubated at 370C, and remaining protein S activity was determined over a 2-h period (Fig. 9) . No significant change in protein S level was observed in normal plasma incubated with the plasma from either brother.
Discussion
The in vitro demonstration by Walker (2) that expression of bovine-activated protein C anticoagulant activity requires protein S suggested to us that functional protein S deficiency, like protein C deficiency, might be manifested as an increased thrombotic tendency. These observations also suggested that protein S deficiency could be monitored in plasma as an inability to respond to activated protein C. A simple Factor Xa one-stage clotting assay done in the presence of activated Whatever the pathophysiologic abnormality, the inheritance pattern suggests that the total lack of functional protein S activity may be a homozygous condition. The levels of 15 and 30% in the parents are consistent with heterozygous individuals, who would produce totally deficient children. Neither parent has had thromboembolic disease, suggesting that even significantly reduced protein S levels may be sufficient to prevent thrombosis. This finding may be similar to protein C deficiency in which certain individuals with significantly reduced levels of protein C (presumably heterozygous for protein C deficiency) do not have a history of thrombosis (16) .
The availability of a rapid, sensitive one-stage functional assay for protein S limits the necessity for immunological detection. This is fortunate since protein S seems to circulate in at least two forms; free, and complexed to C4bp (8) A lw m rockets develop in that portion of the QAE Sepharose elution profile where the protein S-C4bp complex is known to run. More exact measurement of the total immunologically detectable protein S will require methods for separating the complex or detecting protein S while it is bound.
Because the only known clotting abnormality in these patients is a functional protein S deficiency, it is likely that this deficiency causes the observed thrombotic tendency. These findings suggest that, like protein C (5, 6, 17), antithrombin III (18), and plasminogen (19) deficiencies, protein S deficiency should be examined as a possible cause of recurrent thrombosis.
